Carsten Coesfeld’s Post

What are the key themes we are tracking in the MedTech space this year? We're expecting more tuck-in acquisitions, AI-driven collaborations and continued regulatory focus. Check out this piece from Vinita Kailasanath and Sora Park for more. #medtech

Avania has announced a major step in enhancing its position as a top tier medtech focused CRO with the acquisitions of Hull Associates and Ironstone Product Development. This double deal significantly bolsters Avania's capabilities in market access, engineering design, and product development, delivering tailored solutions to every partnership. Hull Associates excels in market access and reimbursement consulting, while Ironstone Product Development specialises in product development across various health sectors. These strategic moves are reinforcing Avania's vision of becoming a global medtech community partner. Sapna Hornyak, Avania's CEO, emphasised that these acquisitions "provide enhanced capabilities to deliver comprehensive, highly customised solutions to every partnership." The value added to Avania's medtech portfolio is immeasurable, With the company remaining steadfast in its commitment to shaping the future of healthcare and driving innovation in the medtech industry. #Medtech #Innovation #Healthcare #Avania

Why is MedTech innovation hard? The need for cross-functional expertise and scale for commercialization leads to complexity. Innovation thrives on collaboration and partnerships both internal and external—Velox brings decades of expertise to elevate every MedTech company!

The MedTech CDMO sector is rapidly evolving, driven by complex medical devices, regulatory demands, and integrated service models. This transformation offers significant investment opportunities, particularly in high-growth areas where innovation aligns with market demand. Together with Nicole Mooljee Damani and Béla J. Anda, I have conducted a study regarding specific recommendations for investors. Read the full study to uncover detailed analyses on targeting these expanding segments through strategic partnerships and acquisitions.   #CDMO #MedTech #StrategyRealized

#innovator #disruptor #visionary 🚀 These are some of the terms that are overused in the biopharma software industry. But we’re making innovation a reality for our European clients who are making the leap to Climb.™ We’re celebrating our Year-1 anniversary in Europe with Richard Coxon at the helm of our EMEA Operations and Diane Garvey leading our business development. And we're already making huge headway with multiple customers in Europe. Join the companies abandoning outdated processes. #modernizeinvivoresearch!

🚀 Novo Holdings Acquires Majority Stake in Single Use Support! 🚀 🌟 Danish company Novo Holdings has acquired a 60% majority stake in the Austrian-based Single Use Support, significantly boosting the company’s global growth trajectory. 🌍💼 About the Acquisition: 🔬 Novo Holdings, a world-leading life sciences investor, has taken a majority stake in Single Use Support, enhancing its global market presence. 👥 Founders Johannes Kirchmair 👋 and Thomas Wurm will remain involved in advisory roles while retaining a minority stake. 👨💼 Christian Praxmarer, who has held various management roles within the company, has been appointed as CEO. Strategic Growth: 🏢 Single Use Support opened a new location in the USA in March 2024, marking a key milestone in its American market expansion. 🌐 Novo Holdings' involvement is set to accelerate the company's growth in key markets, including the USA and Asia. Leadership Statements: Johannes Kirchmair and Thomas Wurm: "With Novo Holdings, we have secured a long-term and stable partner. We look forward to supporting Single Use Support’s continued success." 🤝 Johan Hueffer, Senior Partner, Novo Holdings: "This acquisition underscores our commitment to advancing leading healthcare therapies and technologies. We are excited to integrate Single Use Support into our Life Science Tools & Diagnostics portfolio." 💡 #NovoHoldings #SingleUseSupport #Biopharma #LifeSciences #Innovation #GlobalGrowth #Healthcare #Expansion #Partnership #AdvancedTherapies 🌟🔬🌍

Thrilling news to share: Trinetix has just scored a $10M investment from hypra to drive rapid expansion into the LatAm market and beyond. By making this move, we aim to establish a strong presence in the region and effectively address our clients' challenges in the years ahead. Let's hear the perspective of Sasha Strozhemin, the Co-Founder and CEO of Trinetix: 'With 12 years of market experience, Trinetix has built a diverse list of industry-leading clients. We’ve achieved this by providing a quality service, strengthening our partners’ bottom lines with over 850+ industry experts.  80% senior-level talent in our workforce 85% customer retention rate ...Entering into the LatAm market will allow us to further diversify the team of global tech talent and better cater to our clients' needs. And that’s just the beginning—we intend to triple our company size in the next four years and become a $1B brand within the decade.” 🔗 Check out the press release for more details: https://lnkd.in/egX3zdvy #partnerships #growth #collaboration #expansion

From day one, I’ve been obsessed with learning, innovating, and growing my business. The idea has always been simple: → Learn → Adapt → Integrate By embracing this philosophy, I’ve transformed our processes, making them seamless and efficient. 💪🏻 And each step has brought me closer to realizing my dream of running my business with ease, precision, and automaticity. But I’m not the only one who made this possible. It’s been a team effort of everyone at Intalio! 💪🏻 Together, we’ve scaled from running a small unit to two thriving ones! Here’s to embracing growth, driving innovation, and achieving success—one (purposeful) step at a time! 📈 #innovation #growth #success #pharmaceutical

In the realm of healthcare innovation, investment is just the beginning. At FutureMED VENTURES KZ, we pride ourselves on not merely injecting capital into promising ventures, but on actively cultivating their success. Our unique approach involves seamless collaboration among partners, integrating local expertise from the Kazakh medical industry to provide unparalleled insights and support. One of our core strengths lies in our ability to leverage a vast network of media and technology connections, propelling our portfolio companies toward success. Whether it's raising awareness about their groundbreaking work or forging pivotal partnerships, we are dedicated to clearing the path for their triumphs. By joining forces with FutureMED VENTURES KZ, companies gain access to a strategic advantage unparalleled in the industry. Our collective expertise, combined with our unwavering dedication and precision in guiding businesses through every phase of development, ensures that they are well-equipped for the challenges and opportunities ahead. #FutureMed #MedicalInnovations #VentureCapital

Great inspirational meeting in Danish-Swiss chamber of Commerce today. The topic was “The life Science revolution” and the digitalization readiness. Key takeaways. Digital transformation is difficult and most project never make it in large companies. I do recommend to reach out to Chris Maria Green regarding their conclusions and findings in regards to succeeding. Also. A very interesting set up FUJI has. This in terms of building a modular approach to CDMO and establishing agility and scalability in serving demands for their BTB customers in their global footprint. An interesting perspective is to understand how big CDMO’s maintain a reliable, stable and growth ready service platform to their customers while maintaining an ability to change and adopt the science and tech in an increasingly fast moving phase impacting the future og doing CDMO business. All good food for thought. Thanks Jeppe Stokholm (DSHC), H.E. Mairo Reina(Ambassador of Switzerland to Denmark), Chris Maria Green (Implement), David Stewart (Fujifilm Diosynth Biotechnologies).